Compare Repligen Corporation Common Stock (RGEN) vs Sociedad Quimica y Minera S.A. Common Stock (SQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sociedad Quimica y Minera S.A. Common Stock — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Sociedad Quimica y Minera S.A. Common Stock trades at $61.57 (market cap $17.95B). The key difference: Sociedad Quimica y Minera S.A. Common Stock is the larger of the two by market cap, and Sociedad Quimica y Minera S.A. Common Stock pays a 3.86% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sociedad Quimica y Minera S.A. Common Stock for 6 Days on average.
| RGEN | SQM | |
|---|---|---|
Market Cap | $11.14B | $17.95B |
Volume | 1,259,263 | 910,047 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $95.31 |
52-Week Low | $102.87 | $42.39 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $18.81B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SQM trades at $62.83, up 0.58% today, but technical indicators signal a bearish trend with strong selling pressure. The company delivered mixed Q2 2026 earnings, beating EPS estimates with $2.31 vs. $2.03 expected, while Q1 and Q4 2025 missed expectations. Valuation metrics appear attractive with P/E of 12.93 and EV/EBITDA of 7.09, supported by strong profitability margins including 42.17% gross margin and 23.78% ROE.
Despite near-term technical weakness, SQM's fundamentals remain solid with projected revenue growth to $6.7B in 2026 and net profit margin expansion to 20.62%. The consensus price target of $92.50 suggests 47% upside potential, though lithium price volatility and recent earnings misses present execution risks. Analyst sentiment is mixed with 31% Buy ratings versus 19% Sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sociedad Quimica y Minera S.A. Common Stock
SQM is a mining and chemical company operating in northern Chile. Its businesses include lithium, iodine, specialty plant nutrition, potassium, solar salts, and industrial chemicals.
Read more on SQM →
